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Until now the attention of the investigators in the field of bio-
medical aspects of urea (carbamide) was concentrated on its 
functions at renal level. However, the functional significance
of endogenous urea at extrarenal level in mammalian organism 
(1) has not been satisfactory elucidated yet. Therefore a new 
principal question arises: which are the signals realized by en-
dogenous urea in living animals and humans - extrarenally?
Here we discuss some data obtained with urea used at con-
centrations corresponding to physiological (1.0-8.3 mmol/L) 
and pathological (10-160 mmol/L) ones, in animal and human 
organism - at extrarenal level.
Based on previous work of our research group, we have 
shown for the first time that endogenous urea is able (in
4-fold elevated concentration, via infusion) to antagonize 
dose- and time-dependently some postsynaptic cardiovascu-
lar beta-1,2-adrenergic responses (positive chronotropic and 
vasodepressor effects of isoproterenol at 1, 2, and 4 nmol/kg 
intravenously) in anesthetized mongrel cats and dogs of 
male sex. We pharmacologically characterize urea as an 
endogenous, nonspecific beta-adrenergic receptor antagonist
(ENBARA) (2-7). And, conclude that the endogenous urea 
(under physiological and pathological conditions in animal 
and human organism) realizes endocoid (autacoid) potentials in 
cardiovascular beta-1,2-adrenergic receptors, as consequence 
of the molecular events leading to antagonize and diminish of 
receptor-mediated effects. 
In support of our hypothesis, the following should be con-
sidered: (i) endogenous urea in concentration above 1 mmol/L 
oxidizes tissue thiol groups in proteins forming disulfide bonds
and changing adrenergic receptor activity; urea demonstrates 
“antifatigue capacity better than L-cysteine” (8,9), (ii) in 
agreement with Kushner (10) we propose that the disruption 
of one or two hydrogen bonds in a single alpha-helix in protein 
structure is not enough for an initial protein structural transi-
tion; at least three hydrogen bonds are necessary to be broken. 
That is why it could be accepted that endogenous urea breaks 
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The present position article summarizes briefly own and literature data concerning the characterization of endogenous urea at
extrarenal level in animal and human organism. Both under in vivo and in vitro conditions, we apply urea at physiological and 
pathological concentrations. We  found that urea is an endogenous nonspecific beta-adrenergic receptor antagonist - nonselective,
noncompetitive, reversible and nontoxic. Hence we suggest the endogenous  urea to be included in the list of endocoids (autacoids). 
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RESBARA
Relative Endogenous Specific 
Beta-Adrenergic Receptor Antagonists
beta-arrestin 1 and beta-arrestin 2 –
co-factors of β-adrenergic receptors kinases
β-adrenergic receptor-mediated 
endocytosis-induced down regulation
(schematically presented by 1a, 2a and 3a)
ENBARA
Endogenous Non-specific Beta-Adrenergic 
Receptor Antagonists
A. urea 
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even more than three hydrogen bonds in helix structures of 
beta-adrenergic receptors (6,7), (iii) “urea can break hydrogen 
bonds in aminoacid chains of protein receptor structure” and 
via these molecular events is able to change receptor struc-
ture and function (11), (iv) urea at decreased concentrations 
(2000-60 mmoles/L) inhibits the glucagon-sensitive adenylate 
cyclase system in plasma membranes of rat liver (12), and (v) 
united efforts of French pharmacologists and nephrologists in 
their research at the beginning paid attention to parathormone 
for its “anti-beta adrenoreceptor blockade activity of plasma 
ultra filtrate in two uremic patients” (13); later these authors 
supposed that “some endogenous substances like creatinine, 
urea and parathormone could be involved” (14-16).
It is known that endocoids or autacoids are functioning as 
“own drugs of organism” (17). We agree with these authors 
that “new therapeutic benefits may come through the identi-
fication and development of specific endocoids, and synthesis
of useful analogues of particular endocoids, leading to many 
therapeutic avenues”. The term “endocoid” (endo acoid) or 
“autacoid” (auto acoid), from Greek, means an endogenous 
drug. The term should be applied more specifically to indicate
an endogenous counterpart to a drug obtained by chemical 
synthesis or extracted from plants (18). To meet presently 
established criteria, however, the endocoid must compete 
with an exogenous congener for specific recognition sites (e.g.
receptors or enzyme active sites) that mediate the response 
of target cells, and its action must be blocked by a specific
exogenous antagonist. Of course, classical examples are the 
endorphins and enkephalins, with relation to botanical or syn-
thetic opiat drugs. We accept that “a newly described endocoid 
may represent a previously unrecognized endogenous ligand 
or a more specifc or even unique ligand for a well defined
receptor/mediator system” (18).
 That is why we include the endogenous urea as a first
member of group of endogenous beta-adrenergic receptor 
antagonists (EBARA) (1-7,19-21). Taking into account the 
nonspecific beta-adrenergic receptor antagonistic activity
of endogenous urea, we propose a new classification:  en-
dogenous nonspecific beta-adrenergic receptor antagonists 
(ENBARA), including urea, manganese ions, hydrogen 
peroxide, and L-taurine (reviewed in 6,7), and   
endogenous specific beta-adrenergic receptor antagonists 
(RESBARA), incluing  beta-arrestin 1 and 2 being cofactors 
of five isolated beta-adrenergic receptor kinases (6,7,20,22-
28) (see the Figure). 
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